Orion Portfolio Solutions LLC Sells 2,695 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Orion Portfolio Solutions LLC cut its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 12.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 19,739 shares of the biopharmaceutical company's stock after selling 2,695 shares during the quarter. Orion Portfolio Solutions LLC's holdings in Intra-Cellular Therapies were worth $1,649,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in ITCI. GAMMA Investing LLC raised its holdings in Intra-Cellular Therapies by 46.3% in the 4th quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company's stock valued at $63,000 after buying an additional 240 shares during the last quarter. Venturi Wealth Management LLC acquired a new position in Intra-Cellular Therapies in the 4th quarter valued at approximately $96,000. Wilmington Savings Fund Society FSB acquired a new position in Intra-Cellular Therapies in the 3rd quarter valued at approximately $97,000. Quarry LP raised its stake in shares of Intra-Cellular Therapies by 260.0% during the third quarter. Quarry LP now owns 1,800 shares of the biopharmaceutical company's stock valued at $132,000 after acquiring an additional 1,300 shares during the last quarter. Finally, Barlow Wealth Partners Inc. acquired a new position in shares of Intra-Cellular Therapies during the fourth quarter worth $184,000. 92.33% of the stock is owned by institutional investors and hedge funds.

Intra-Cellular Therapies Price Performance

Shares of ITCI stock remained flat at $131.87 on Tuesday. The company has a 50-day moving average of $129.91 and a 200 day moving average of $102.78. The stock has a market capitalization of $14.05 billion, a price-to-earnings ratio of -151.57 and a beta of 0.69. Intra-Cellular Therapies, Inc. has a 1 year low of $64.09 and a 1 year high of $131.98.

Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last posted its quarterly earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. The firm had revenue of $199.22 million for the quarter, compared to analyst estimates of $205.08 million. Equities research analysts expect that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently issued reports on ITCI shares. Canaccord Genuity Group lowered Intra-Cellular Therapies from a "buy" rating to a "hold" rating and raised their target price for the stock from $119.00 to $132.00 in a research report on Friday, January 31st. Needham & Company LLC reissued a "hold" rating on shares of Intra-Cellular Therapies in a research note on Friday, February 21st. Mizuho lowered Intra-Cellular Therapies from an "outperform" rating to a "neutral" rating and cut their price objective for the stock from $140.00 to $132.00 in a research note on Monday, February 24th. Leerink Partnrs cut Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a report on Monday, January 13th. Finally, Piper Sandler restated a "neutral" rating and set a $132.00 price target (up previously from $107.00) on shares of Intra-Cellular Therapies in a report on Tuesday, January 14th. Eleven investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, Intra-Cellular Therapies presently has a consensus rating of "Hold" and a consensus price target of $106.23.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.